Claravis: adverse event reports filed with FDA

7,019

reports as suspect product

0% of all reports · about 314 a year

217

reports, 12 months to June 2026

243 in the 12 months before

66.4%

marked serious by the reporter

49.6% across the class

1.1%

record death among outcomes, as reported

79 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Claravis reports recording the termmedian drug in retinoid

1. Unintended pregnancy25.9%1,816
2. Depressionlow mood10.4%733
3. Suicidal ideationthoughts of suicide6.8%475
4. Mood altereda change in mood4.8%338
5. Anxietyanxiety4.3%303
6. Drug exposure during pregnancythe medicine was taken during pregnancy4.1%290
7. Inflammatory bowel disease3.9%275
8. Headachehead pain3.4%241
9. Arthralgiajoint pain3.2%225
10. Dry skindry skin2.9%206
11. Abortion spontaneousmiscarriage2.6%183
12. Treatment noncompliancethe treatment was not taken as directed2.6%181
13. Blood triglycerides increased2.6%180
14. Maternal exposure during pregnancythe mother took the medicine during pregnancy2.5%175
15. Abortion induced2.2%151
16. Lip dry2.2%151
17. Mood swingsmood swings1.9%136
18. Acneacne1.8%127
19. Depressed moodlow mood1.7%117
20. Drug ineffectivethe medicine did not work as expected1.5%106
21. Pregnancypregnancy1.4%101
22. Fatiguetiredness1.4%100
23. Abdominal painstomach or belly pain1.4%96
24. Back painback pain1.4%96
25. Epistaxisnosebleed1.3%93
26. Suicide attempta suicide attempt1.2%86
27. Malaisegeneral feeling of being unwell1.2%83
28. Nauseafeeling sick1.2%82
29. Diarrhoealoose or frequent stools1.1%75
30. Pregnancy test false positive1.1%75

Top 30 of 472 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 11 drugs in the retinoid class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 65,827 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 99.2% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 7,019 reports.

Drugs most often listed in the same reports

Other products listed in reports where Claravis is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the retinoid class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Claravis as a suspect or interacting product; reports listing it only as a concomitant medication (324) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.